Mizuho Upgrades Waters on Improving Pharma Picture

May 21, 2012

|

NEW YORK (GenomeWeb News) – Mizuho Securities today upgraded Waters' stock to Buy from Neutral, citing the firm's exposure to the pharma industry, its presence in emerging markets, and its "strong" product cycle.

Mizuho also increased the price target on Waters' stock to $92 from $84. The investment firm lowered full-year 2012 revenue estimates to $1.89 billion from $1.91 billion, while maintaining an EPS estimate of $5.10.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Here We Are Again

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

In the Pink

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

All Tied Up in a Bow

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

This Week in PNAS

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

Main menu